1-4 of 4
P Carde
Close
Sort by
Journal Articles

Relative Risk of Cardiovascular Disease after Treatment for Aggressive Non-Hodgkin’s Lymphoma.

E. C. Moser, E. M. Noordijk, MD, PhD, F. E. van Leeuwen, PhD, S. le Cessie, PhD, J. W. Baars, MD, PhD, J. Thomas, MD, PhD, P. Carde, MD, PhD, M. van Glabbeke, PhD, J. H. Meerwaldt, MD, PhD, J. C. Kluin-Nelemans, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 2831.
https://doi.org/10.1182/blood.V106.11.2831.2831
Published: 2005
Journal Articles

The Tetrapeptide Acetyl-N-Ser-Asp-Lys-Pro (Goralatide) Protects From Doxorubicin-Induced Toxicity: Improvement in Mice Survival and Protection of Bone Marrow Stem Cells and Progenitors

A. Massé, L.H. Ramirez, G. Bindoula, C. Grillon, J. Wdzieczak-Bakala, K. Raddassi, E. Deschamps de Paillette, J.M. Mencia-Huerta, S. Koscielny, P. Potier, F. Sainteny, P. Carde
Journal: Blood
Blood (1998) 91 (2): 441–449.
https://doi.org/10.1182/blood.V91.2.441
Published: 1998
Journal Articles

Carcinoma cell leukemia [letter]

F Nasr, C Corti, P Carde, V Ribrag, F Valensi, C Bayle, AG Turhan, J Bosq
Journal: Blood
Blood (1996) 88 (6): 2355–2357.
https://doi.org/10.1182/blood.V88.6.2355.bloodjournal8862355
Published: 1996
Journal Articles

Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987

M Tubiana, M Henry-Amar, P Carde, JM Burgers, M Hayat, E Van der Schueren, EM Noordijk, A Tanguy, JH Meerwaldt, J Thomas
Journal: Blood
Blood (1989) 73 (1): 47–56.
https://doi.org/10.1182/blood.V73.1.47.47
Published: 1989